AbbVie (ABBV) Cash from Investing Activities Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
-78.48% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-32.26% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
-4.78% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-62.97% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-36.21% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
60.61% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-38.13% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
14.56% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
-4.78% |
| Dec 31, 2025 |
-48.36% |
| Sep 30, 2025 |
-65.56% |
| Jun 30, 2025 |
-122.97% |
| Mar 31, 2025 |
22.70% |
| Dec 31, 2024 |
-17.85% |
| Sep 30, 2024 |
-137.66% |
| Jun 30, 2024 |
-65.75% |
| Mar 31, 2024 |
-203.79% |
| Dec 31, 2023 |
-8.46% |
| Sep 30, 2023 |
31.52% |
| Jun 30, 2023 |
78.77% |
| Mar 31, 2023 |
-56.98% |
| Dec 31, 2022 |
10.02% |
| Sep 30, 2022 |
-2.28% |
| Jun 30, 2022 |
43.07% |
| Mar 31, 2022 |
-289.14% |
| Dec 31, 2021 |
-59.35% |
| Sep 30, 2021 |
13.88% |
| Jun 30, 2021 |
-32.99% |
| Mar 31, 2021 |
8.54% |
| Dec 31, 2020 |
-72.35% |
| Sep 30, 2020 |
-119.26% |
| Jun 30, 2020 |
-385.04% |
| Mar 31, 2020 |
42.65% |
| Dec 31, 2019 |
-72.89% |
| Sep 30, 2019 |
107.43% |
| Jun 30, 2019 |
68.06% |
| Mar 31, 2019 |
73.54% |
| Dec 31, 2018 |
1.60% |
| Sep 30, 2018 |
-48.77% |
| Jun 30, 2018 |
27.13% |
| Mar 31, 2018 |
20.00% |
| Dec 31, 2017 |
-56.92% |
| Sep 30, 2017 |
63.73% |
| Jun 30, 2017 |
42.37% |
| Mar 31, 2017 |
4.97% |
| Dec 31, 2016 |
-43.70% |
| Sep 30, 2016 |
40.90% |
| Jun 30, 2016 |
-173.45% |
| Mar 31, 2016 |
-43.91% |
| Dec 31, 2015 |
-12.97% |
| Sep 30, 2015 |
34.12% |
| Jun 30, 2015 |
-295.65% |
| Mar 31, 2015 |
-62.35% |